Physician profile
Scott H Beegle
NPI 1437159837
$1,884,609.33
in general payments reported to CMS, 2019-2025
32 companies · $353K in 2025
The $353K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235K · 2020: $145K · 2021: $210K · 2022: $314K · 2023: $286K · 2024: $341K · 2025: $353K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $799K · Travel and Lodging: $65K · Consulting Fee: $60K · Food and Beverage: $32K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $20K · Honoraria: $3,000 · Education: $942 · Gift: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $799,088.24 |
| Travel and Lodging | $64,844.73 |
| Consulting Fee | $60,396.19 |
| Food and Beverage | $32,393.23 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $19,563.00 |
| Honoraria | $3,000.00 |
| Education | $942.21 |
| Gift | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $553,050.44 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Genzyme Corporation | $392,946.64 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $226,169.06 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $123,635.49 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121,626.94 | 2019-2025 | Ofev |
| Csl Behring | $81,747.62 | 2019-2025 | Kcentra, Hizentra |
| Janssen Pharmaceuticals, INC | $63,053.45 | 2019-2024 | Xarelto |
| Genentech USA, INC. | $57,821.83 | 2019-2025 | Xolair |
| Amgen INC. | $51,861.14 | 2021-2025 | Tavneos, Otezla |
| Insmed, INC. | $41,301.85 | 2019-2025 | Arikayce |
| Astellas Pharma US INC | $38,728.39 | 2019-2025 | Cresemba |
| Shionogi INC | $33,494.12 | 2022-2025 | Fetroja |
| Alexion Pharmaceuticals, INC. | $27,002.37 | 2019-2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $22,463.18 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $15,394.67 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $8,852.80 | 2020-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $7,573.12 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $4,110.55 | 2019 | |
| Verona Pharma, INC. | $3,780.28 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $2,201.73 | 2021-2025 | Tyvaso, Steen Solution, Tyvaso |
| Pfizer INC. | $2,030.84 | 2019-2020 | |
| Nabriva Therapeutics, Plc | $1,784.36 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $1,680.00 | 2021 | |
| Viiv Healthcare Company | $1,600.00 | 2019 | |
| Genentech, INC. | $433.68 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $123.35 | 2025 | Terlivaz |
| Zambon USA Ltd. | $54.36 | 2022 | |
| Electromed, INC. | $37.17 | 2021 | |
| Grifols USA, LLC | $27.32 | 2025 | Prolastin-C Liquid |
| Teleflex LLC | $22.58 | 2024 | Arrow |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Beegle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.